^
    3d
    EPCORE CLL-1: Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome (clinicaltrials.gov)
    P1/2, N=195, Active, not recruiting, Genmab | Recruiting --> Active, not recruiting | N=424 --> 195
    Enrollment closed • Enrollment change
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Jaypirca (pirtobrutinib) • Epkinly (epcoritamab-bysp)
    3d
    Characterisation of Bespoke Patient-Derived In Vitro Models of Ewing Sarcoma. (PubMed, Cancers (Basel))
    Consistent with the longer doubling time, PDES were more resistant to doxorubicin, etoposide and vincristine and ionising radiation (p < 0.0001) than cell lines. PDES were sensitive to mTKIs (cabozantinib, lenvatinib, and regorafenib), and trabectedin. The response of PDES to drugs in vitro reflects the clinical experience of patients. Models incorporating PDES cells may positively contribute to the preclinical pipeline.
    Preclinical • Journal
    |
    EWSR1 (EWS RNA Binding Protein 1)
    |
    Lenvima (lenvatinib) • doxorubicin hydrochloride • Cabometyx (cabozantinib tablet) • Stivarga (regorafenib) • etoposide IV • vincristine • Yondelis (trabectedin)
    4d
    GOLSEEK-1: Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma (clinicaltrials.gov)
    P3, N=850, Active, not recruiting, Celgene | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2)
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • golcadomide (CC-99282)
    5d
    BDH-MCL01: EDOCH Alternating With DHAP for New Diagnosed Younger MCL (clinicaltrials.gov)
    P4, N=55, Completed, Institute of Hematology & Blood Diseases Hospital, China | Unknown status --> Completed
    Trial completion
    |
    cisplatin • Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisone • thalidomide
    5d
    A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma (clinicaltrials.gov)
    P3, N=165, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2030 --> Dec 2027 | Trial primary completion date: Dec 2030 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    NF1 (Neurofibromin 1)
    |
    carboplatin • Koselugo (selumetinib) • vincristine
    5d
    B-Cell Lymphoma Following an Indolent Course Over 30 Years with Immunophenotypic Changes at Each Recurrence. (PubMed, Eur J Case Rep Intern Med)
    Diffuse large B-cell lymphoma (DLBCL) can undergo stepwise immunophenotypic and molecular evolution over decades, progressing from a germinal Center B-cell-like (GCB)-like phenotype to an activated B-cell -like/non-GCB pattern (MUM1+, CD30+) and ultimately to an aggressive anaplastic variant.The cell-of-origin profile and its associated molecular features are not necessarily static; thus, therapeutic strategies for relapsed DLBCL should be tailored to the current disease state rather than relying on the signature at initial diagnosis.Longitudinal re-evaluation through repeat biopsies is imperative to capture the evolving landscape of the malignancy, ensuring that treatment selection is guided by the most recent pathological and molecular findings.
    Journal
    |
    CD20 (Membrane Spanning 4-Domains A1) • TNFRSF8 (TNF Receptor Superfamily Member 8) • IRF4 (Interferon regulatory factor 4)
    |
    CD20 positive • TNFRSF8 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • bendamustine • Pinorubin (pirarubicin)
    7d
    Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients (clinicaltrials.gov)
    P3, N=482, Completed, Gustave Roussy, Cancer Campus, Grand Paris | Unknown status --> Completed
    Trial completion
    |
    LDH elevation
    |
    Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • vincristine
    7d
    Intergroup Trial for Children or Adolescents With Primary Mediastinal Large B-Cell Lymphoma: DA-EPOCH-Rituximab Evaluation (clinicaltrials.gov)
    P2, N=47, Completed, Gustave Roussy, Cancer Campus, Grand Paris | Active, not recruiting --> Completed
    Trial completion
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine
    7d
    A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma (clinicaltrials.gov)
    P2, N=40, Recruiting, University of Rochester | Trial primary completion date: Jun 2025 --> Jun 2026
    Trial primary completion date
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone
    9d
    Pharmacological Potential of Chalepensin from Ruta chalepensis L.: Acute Toxicity and In Vivo Antitumor Activity in the L5178Y-R Murine Model. (PubMed, J Ethnopharmacol)
    Chalepensin demonstrates promising antitumor activity against L5178Y-R murine lymphoma, along with a favorable acute toxicity profile. These findings support its potential for further preclinical development and warrant additional studies to elucidate its molecular mechanisms and long-term safety.
    Preclinical • Journal
    |
    CCNA2 (Cyclin A2) • CDK2 (Cyclin-dependent kinase 2)
    |
    vincristine
    10d
    PEPN22P1: Vincristine Pharmacokinetics in Infants (clinicaltrials.gov)
    P=N/A, N=83, Active, not recruiting, Children's Oncology Group | Trial completion date: Dec 2025 --> Sep 2026 | Trial primary completion date: Dec 2025 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    vincristine
    10d
    NCI-2018-02699: Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma (clinicaltrials.gov)
    P2, N=30, Active, not recruiting, David Bond, MD | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Opdivo (nivolumab) • Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisone • Truxima (rituximab-abbs)